Lilly China CIO: Three Drivers of Digital Innovation in Pharmaceutical Enterprises

A few days ago, Lilly China and Microsoft China held a strategic cooperation signing ceremony and press conference in Shanghai. The two parties said that based on Lilly's leading market position and industry insight in the healthcare industry, as well as forward-looking exploration in the field of digital innovation, combined with Microsoft's cutting-edge artificial intelligence technology, cloud computing services and ecosystem advantages, jointly promote services and technology. And extensive cooperation in the market field to create a new industry of "artificial intelligence + medical health".

Julio Gay-Ger, President and General Manager of Lilly China, said: "Lilly is willing to actively promote the innovative application of artificial intelligence, cloud computing and other technologies in the field of medical and health, and explore strategic innovation with Microsoft through strategic cooperation with Microsoft. Being able to be medically healthy and helping to implement the 'Healthy China 2030' planning outline will ultimately benefit the majority of patients."

Lilly China and Microsoft China strategic cooperation signing ceremony guests photo, corporate photo

After the press conference, Artex.com exclusively interviewed Mr. Bai Liuchen, vice president and CIO of Lilly China's Information Technology Department. He introduced Lilly's attempts at digital innovation and the direction of the transformation of the pharmaceutical industry driven by digital technology.

Lilly Bailiu Chen, Vice President and CIO of China's Information Technology Department, courtesy of respondents

Practice digital innovation, and be loyal to the tide

The digital innovation in the pharmaceutical industry is an important topic of concern for the arterial network. We have seen that new technologies such as artificial intelligence, big data, Internet medical care, and the Internet of Things are being applied in all aspects of the pharmaceutical industry to reshape the pharmaceutical industry. And top pharmaceutical companies are also actively embracing new technologies.

Bai Liuchen believes that pharmaceutical companies actively embrace digital innovation with three external drivers: one is environmental change, the other is technology driven, and the third is customer demand changes.

Taking the Chinese market as an example, from the national medical reform to the “Internet + medical health” to the grading diagnosis and treatment, the entire medical environment has changed, which has new requirements for the role of pharmaceutical companies in the medical industry . Artificial intelligence, big data, cloud and other technologies have begun to fall in all walks of life, and technology maturity is getting higher and higher. Medical care is a very important scene.

In the past, pharmaceutical companies played a role in the medical industry as drug providers, but in the new environment, patients need more than just drugs, but integrated solutions for diseases, in healthy lifestyles, early diagnosis, treatment, and rehabilitation. At the same time, higher requirements were put forward. Digital innovation is an important path for pharmaceutical companies to respond to market changes and meet customer needs.

Lilly has become a pioneer in the digital transformation wave, driven by Lilly's IT department and cross-departmental collaboration. Lilly's layout in the digital field has created three major directions: digital traditional platform applications, independent value platforms and ecosystem cooperation.

In the application of digital traditional platform, the main objectives are to work innovate and improve work efficiency, including: launching the eP2P online conference mode, improving the doctor's conference platform, allowing academic exchanges to break through the space, and greatly improving the frontier medicine. The efficiency and breadth of knowledge dissemination; the internal support sales team masters new digital tools, vividly and visually display product-related information, and can also apply sales charts and other data charts to improve work efficiency and user experience.

In terms of autonomous value platforms, a series of innovative initiatives have been launched for patients and doctors. E.g:

Patient side. Lilly combines its advantages in diabetes expertise and management experience to launch the diabetes management app “Diabetes Heart” in the industry. The app incorporates the internationally recognized “five-carriage” theory of diabetes management, providing patients with daily guidance services in sports, diet, disease management knowledge and monitoring of blood glucose. As of now, "Diabetes Hearts" has more than 1.4 million downloads and is one of the preferred disease management apps for people with diabetes.

Doctor's side. Lilly has innovatively launched a WeChat-based one-stop doctor service platform, “Ceremony,” which facilitates communication, interaction, and service with doctors. In the "medical doctor", it can realize the functions of meeting invitation, pre-conference information acquisition, conference sign-in, real-time voting, real-time Q&A, questionnaire survey, medical literature search, online inquiry and even patient management. At present, the "medical doctor" platform has been on the first anniversary of the launch, completed 12 release iterations within one year, upgraded 20 new features, and accumulated more than 70,000 users.

In terms of eco-cooperation, at the end of 2017, Lilly and Tencent and Lilac Park joined forces to create a seamlessly integrated diabetes management integrated solution called “Excellent Diabetes Care Project (LCCP)”. By providing high-quality medicines, pioneering technologies and customized services, the project helps doctors optimize treatment and help patients achieve their treatment goals. At present, the project has 50,000 patients enrolled, and its blood glucose control has achieved remarkable results compared with the past.

Bai Liuchen divided Lilly's digital innovation in China into three phases: Digital 1.0 is the application of the traditional model; Digital 2.0 is the platform, omni-channel integration, online and offline access, the establishment of the ecosystem and the internal digital capabilities. Strengthening; Digital 3.0 is to apply AI, big data and cloud technology to all directions in a more in-depth and comprehensive manner, providing better support and services both internally and externally.

The cooperation with Microsoft China is the beginning of Lilly Digital Innovation 3.0. Bai Liuchen told the arterial network that the possible cooperation directions between the two sides include: exploring the application of artificial intelligence in medical imaging and disease screening; using natural language processing, dialogue robots, knowledge maps and other technologies to develop physician interactive services, patient support and education and Employee efficiency tools; use natural language processing, machine translation to support the richness and timeliness of medical content; use enterprise-level office automation applications to improve employee efficiency; Microsoft Azure will also play an important role in the implementation of application systems.

Balance between direction and speed, pursue the right place and the right place

Bai Liuchen said that digital innovation is a very wide-ranging issue, including internal and external synergies, long-term and short-term effects, and input-output effects. It is a question of “time, place, and people”.

Under the wave of digital innovation, the IT department of pharmaceutical companies should play a more important role and play a more proactive role. Previously, the IT department might be a support department to meet demand. However, under the digital innovation environment, the IT department should play the role of “catalyst” and “adhesive”, create a function, meet the demand, drive the business and business model innovation, and create a “catalyst” for innovation; External suppliers and partners can be found and closely adhered to the business.

"Digital transformation initiatives can not be seen as a project, but should be a product that can implement iterative products according to market demand, technical conditions, etc., so that there will be long-lasting vitality." Bai Liuchen said.

The digital innovation of pharmaceutical companies must consider the issue of input and output. Too much attention to short-term interests may limit the direction, and only focusing on long-term interests may have very high opportunity costs. Therefore, we should find a balance between long-term and short-term effects. In the case of ensuring the direction, we will gradually develop and cultivate long-term competitiveness.

Enterprises will also encounter various challenges in the process of digital innovation, such as internal digital capabilities, talents, processes and other challenges. Internal digitalization can't keep up, and external digitalization is created, and the effect of external digitalization will soon be affected. If the user doesn't have a good experience and can't get what they need, the channel will slowly die. This is very dangerous. Therefore, in the process of advancing the digital transformation, internal and external coordination and cooperation are needed. Only by diligently practicing "internal strength" can we make a better digital transformation.

And talents often play the most crucial role. Under the wave of digital transformation in the industry, excellent talents are very scarce. Lilly's approach is to build a high-level talent team through external recruitment and internal training, which not only meets the needs of digital innovation within the team, but also delivers talent to other business units and innovation departments in other parts of the world.

Finally, Bai Liuchen said that digital innovation does not only occur in the pharmaceutical industry, but in the entire medical and health field, digital technology can play a greater value. For example, "Internet + medical health", remote diagnosis and treatment can solve the problem of uneven distribution of medical resources, imbalance between supply and demand; AI auxiliary diagnosis and treatment can improve the doctor's work efficiency and diagnosis and treatment, and reduce the busy and repetitive work of doctors. Of course, the convenience and ease of use of digital tools is also an important challenge.

“By working together outside the industry, not only pharmaceutical companies, but also medical service providers, as well as every link in the health care industry chain, can benefit from the application of technology. In the near future, perhaps 5-10 Within a year, we can see digital innovation and AI bring earth-shaking changes to the industry.” Bai Liuchen said.

Others Finished Drugs

Paclitaxel Injection,Diosmin Tablet Uses,Dexamethasone Phosphate Injection,Vecuronium Bromide Injection

NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com